Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis

OBJECTIVE: Neratinib plus capecitabine (Ner+Cap) were proved to be clinically beneficial as a third-line treatment for women with human epidermal growth factor receptor-2 (HER2) positive metastatic breast cancer (MBC). The objective of this study was to evaluate the cost-effectiveness of Ner+Cap fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yue, Dong, Zhu, Wang, Jiangfeng, Fang, Qingxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667994/
https://www.ncbi.nlm.nih.gov/pubmed/36379662
http://dx.doi.org/10.1136/bmjopen-2022-065299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667994/
https://www.ncbi.nlm.nih.gov/pubmed/36379662
http://dx.doi.org/10.1136/bmjopen-2022-065299

Ejemplares similares